FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives-Reference-Cited by-同舟云学术

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives

Published:2020-11 Issue:5 Volume:111 Page:
ISSN:0026-4806
Container-title:Minerva Medica
language:
Short-container-title:Minerva Med

Author:

Mosquera Orgueira Adrián,Bao Pérez Laura,Mosquera Torre Alicia,Peleteiro Raíndo Andrés,Cid López Miguel,Díaz Arias José Á.,Ferreiro Ferro Roi,Antelo Rodríguez Beatriz,González Pérez Marta S.,Albors Ferreiro Manuel,Alonso Vence Natalia,Pérez Encinas Manuel M.,Bello López José L.,Martinelli Giovanni,Cerchione Claudio

Publisher

Edizioni Minerva Medica

Subject

General Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R10Y2020N05A0427

Reference98 articles.

1. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

2. Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemias

3. Acquired copy number alterations in adult acute myeloid leukemia genomes

4. Genomic Classification and Prognosis in Acute Myeloid Leukemia

5. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies;Drug Resistance Updates;2024-05

2. A Review on the Synthesis and Anticancer Potentials of Imidazothiazole Derivatives;Mini-Reviews in Medicinal Chemistry;2023-09

3. The Application of Pyrrolo[2, 3-d]pyrimidine Scaffold in Medicinal Chemistry from 2017 to 2021;Mini-Reviews in Medicinal Chemistry;2023-06

4. Design, synthesis, and biological evaluation with molecular dynamics study of novel pyrazolo[3,4-d]pyrimidine derivatives as anti-cancer agents;RSC Advances;2023

5. Biologicals and small molecules as target-specific cancer chemotherapeutic agents;Medicinal Chemistry of Chemotherapeutic Agents;2023